



FOR IMMEDIATE RELEASE

RCRC IRB Announces Addition of Third Review Board

Austin, Texas, September 02, 2013 - RCRC IRB announced today that it has added an additional review board for continued customer service enhancement. Alexander Kenaston chairs the additional board. Dr. Kenaston has over ten years' experience in the IRB and research fields. Dr. Jennifer Christensen, a previous researcher, is the vice-chair of the new board. Both Dr. Kenaston and Dr. Christensen have experience serving on academic institutional IRBs and commercial or independent IRBs.

"RCRC has two boards meeting on Monday and Wednesday, respectively," says RCRC's Executive Director, Priscilla Short. "The additional third board meets on Friday, which allows our administrative staff additional resources to ensure that new protocol submissions are evenly distributed between boards and that submissions are reviewed and approval documents returned to clients as quickly as possible."

Each of RCRC's boards is diverse in expertise and able to review a variety of therapeutic areas involving drugs and devices. Board members are also experienced in reviewing research involving vulnerable populations. Once a new protocol submission is received and deemed to be complete, turnaround time of board-approved documents to the client is approximately 2 business days.

About RCRC IRB

RCRC IRB is a fully accredited, leading provider of professional IRB services, providing IRB review for pharmaceutical, biotech, and medical device clients in the U.S. and internationally. RCRC provides ethical review for all phases of research in a variety of therapeutic areas and has extensive experience in single-site trials, multi-site trials, and large-scale trials. RCRC offers three weekly review board meetings and a 24-48 hour turnaround time. For further information visit www.rcrcirb.com.

For Additional Information Contact:

Priscilla Short
Executive Director
RCRC Independent Review Board
+1 512.380.1244